NCT01580618 2026-04-14
Tenecteplase (TNK) for Loculated Pleural Effusions in Patients With Malignancy
Kaiser Permanente
Phase 2/3 Terminated
Clinical Trials
17 trialsNCT05131776 2026-03-23
EUS-guided Intra-tumour Injection of OncoSil for Locally Advanced Pancreatic Carcinoma.
Chinese University of Hong Kong
Phase 2/3 Terminated
NCT04817761 2026-02-18
SPARK-ALL: Calaspargase Pegol in Adults With ALL
Servier
Phase 2/3 Terminated
NCT03870750 2026-01-12
Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases
Fred Hutchinson Cancer Center
Phase 2/3 Terminated
NCT05171166 2025-12-18
Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.
Peking University
Phase 2/3 Terminated
NCT05454358 2025-12-15
Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP
Fudan University
Phase 2/3 Terminated
NCT05694013 2025-10-22
ORIGAMA
Hoffmann-La Roche
Phase 2/3 Terminated
NCT05130866 2025-10-07
POPLAR-NF2
Recursion Pharmaceuticals Inc.
Phase 2/3 Terminated
NCT05870748 2025-09-23
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Sutro Biopharma, Inc.
Phase 2/3 Terminated
NCT04695977 2025-09-05
CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma
Regeneron Pharmaceuticals
Phase 2/3 Terminated
NCT05149807 2025-08-20
Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2/3 Terminated
NCT06321068 2025-08-14
BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer
Bio-Thera Solutions
Phase 2/3 Terminated
NCT04159155 2025-08-12
CAN-STAMP
University Health Network, Toronto
Phase 2/3 Terminated
NCT05269355 2025-06-13
SUNRISELMS
PTC Therapeutics
Phase 2/3 Terminated
NCT00518869 2025-06-04
Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue
PhytoHealth Corporation
Phase 2/3 Terminated
NCT04856787 2025-05-18
A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2/3 Terminated
NCT02807181 2025-05-09
SIRCCA
Sirtex Medical
Phase 2/3 Terminated